Renaissance Technologies’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Renaissance Technologies’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,752	Closed	-$773K	–	3868
2021 Q1	$773K	Buy	+11,752	New	+$915K	﹤0.01%	2725
2020 Q3	–	Sell	-244	Closed	-$9K	–	3783
2020 Q2	$9K	Buy	+244	New	+$8.35K	﹤0.01%	3382
2016 Q3	–	Sell	-556	Closed	-$109K	–	3530
2016 Q2	$109K	Buy	556 +143	+35%	+$65.9K	﹤0.01%	3149
2016 Q1	$177K	Buy	413 +204	+98%	+$72.9K	﹤0.01%	3122
2015 Q4	$79K	Buy	+209	New	+$65.5K	﹤0.01%	3133

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Verdence Capital Advisors Hunt Valley, Maryland $1.9B AUM 36.41% 1-Year Est. Return

Renaissance Technologies's DMK Position: Q2 2021 in Review

Renaissance Technologies sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2021, closing a stake of 11,752 shares — an estimated $773K sold.

Renaissance Technologies first reported a position in DMK in Q4 2015 and held it in 5 quarters. The position peaked at $773K in Q1 2021. 51 funds tracked by Wall St. Rank hold DMK as of Q2 2021.

Renaissance Technologies reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2021 after selling out during the quarter.
Renaissance Technologies sold 11,752 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2021, an estimated $773K.
Renaissance Technologies first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2015 and held it in 5 quarters.
Renaissance Technologies's DMK Pharmaceuticals Corporation Common Stock position peaked at $773K in Q1 2021.
51 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2021.

Based on Renaissance Technologies's 13F filing for Q2 2021, filed 13 Aug 2021.